Louise Catherine Connell, MB BCh BAO, BMedSc
Gastrointestinal Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Colon Cancer
- Rectal Cancer
- Other Gastrointestinal Cancers
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist whose practice is dedicated to caring for people with gastrointestinal cancers. These include colon cancer, rectal cancer, and appendiceal cancer. I also have expertise in treating hepatobiliary cancers.
I specialize in systemic chemotherapy, where the treatment circulates throughout the body, and regional chemotherapy, meaning the drug is delivered directly to the liver or abdomen. I see patients at MSK’s Rockefeller Outpatient Pavilion, in Manhattan.
Read more
The goal of my research is to develop new, more-personalized therapies for people with colorectal and hepatobiliary cancers. For example, we are working to develop immunotherapy and molecular-based approaches to effectively treat these diseases. I have a particular interest in advancing our understanding of colorectal cancers at the molecular level so that we can learn how and why they grow and spread.
As a medical student unsure of the exact path my career would take, my family was impacted by cancer. The journey that followed influenced me both in terms of my career choices and goals, and also how I care for patients today. My experience being on the other side of the consultation desk helped me to understand and appreciate what patients and their families go through after receiving a cancer diagnosis.
When caring for my patients, I aim to provide the best evidence-based treatments and to surround them with compassion. I place a great deal of emphasis on communication to help reduce their distress and maximize their quality of life.
A gastrointestinal (GAS-troh-in-TES-tih-nul) oncologist is a cancer doctor with special training in the gastrointestinal (GI) system. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Colon Cancer
- Rectal Cancer
- Other Gastrointestinal Cancers
- Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer
Education
- MB BCh BAO BMedSc, University College Cork, Ireland
Residencies
- Internal Medicine - Royal College of Physicians of Ireland
Awards and Honors
- Irish Society of Medical Oncology Scholarship Award (2013)
- Ainsworth Scholarship (2014)
- American Society of Clinical Oncology (ASCO) Young Investigator Award (2016)
Fellowships
- Medical Oncology - Royal College of Physicians of Ireland
- Advanced Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine (Ireland)
- Medical Oncology (Ireland and Europe)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Connell sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Connell
- A Phase II Study Evaluating the Effectiveness of a Lower Dose of Chemoradiation to Treat Early-Stage Anal Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. Connell LC, Boucher TM, Chou JF, Capanu M, Maldonado S, Kemeny NE.J Surg Oncol. 2017 Mar;115(4):480-487. doi: 10.1002/jso.24536. Epub 2016 Dec 23.PMID:28008623
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D’Angelica M, Kemeny NE.J Surg Oncol. 2016 Nov;114(6):655-663. doi: 10.1002/jso.24399. Epub 2016 Aug 26.PMID:27566258
The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Connell LC, Mota JM, Braghiroli MI, Hoff PM. Curr Treat Options Oncol. 2017 Apr;18(4):23. doi: 10.1007/s11864-017-0463-3. PMID:28391421
Read more
Combined Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Connell LC, Harding JJ, Shia J, Abou-Alfa GK.Chin Clin Oncol. 2016 Oct;5(5):66. doi: 10.21037/cco.2016.10.02. PMID: 27829279
Advanced Hepatocellular Cancer: The Current State of Future Research. Connell LC, Harding JJ,Abou-Alfa GK. Curr Treat Options Oncol. 2016 Aug;17(8):43. doi: 10.1007/s11864-016-0415-3. PMID:27344158
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Ann Oncol. 2015 Dec;26(12):2375-91. PMID:27072927
Visit PubMed for a full listing of Dr. Connell’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Louise Catherine Connell discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
